Landmark 157 · Trial in people
PARAISO prasinezumab Phase 3
The main answer. It will show whether prasinezumab slows Parkinson's over at least 2 years.
In short
The first Phase 3 of an anti-synuclein antibody; about 900 people, primary completion estimated June 2029.
- What it is
- Trial in people
- Outcome
- Result due Jun 2029
- When
- 2025–2029
- Size
- 900 people · Phase 3
- Approach
- Clear the bad protein
- Research lane
- Synuclein misfolding & spread
- Trial registry
- NCT07174310
- Last checked
- 18 Oct 2026
The research record
This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".
Who
Roche/Genentech. Registry NCT07174310.
What is being tested
Prasinezumab, the antibody from landmark 63, against placebo in about 900 people. Started 24 Nov 2025; recruiting.
What would count as success
The primary outcome is time to a confirmed motor progression event on MDS-UPDRS part III, through at least week 104. A hazard ratio clearly below 1 would be the first proof that targeting synuclein slows Parkinson's.
Sources
- ClinicalTrials.gov NCT07174310
- Genentech release, 15 Jun 2025
- Not yet verified: secondary endpoints and enrolment progress.
How it connects
Built on
- builds on Prasinezumab: PASADENA and PADOVA · 2022
Led to
None recorded.